Transcenta Holding Limited · HKEX:6628
Transcenta — H1 2026 Earnings Presentation
37 slides from Transcenta's earnings presentation, Aug 31, 2026
Slide 1: 2026 Interim Results
Stock Code: 6628.HK 2026 Interim Results August 31, 2026
Slide 2: Disclaimer
Disclaimer • The information and opinions contained in this presentation are provided as of the date of this presentation, are subject to change without notice and will not be updated or otherwise revised to reflect any developments, which may occur after the date of the presentation. • This present
Slide 3: Today's Agenda and Speakers
Today’s Agenda and Speakers 1H 2026 Performance Highlights Pipeline Progress Financial Summary and Strategic Partnerships Outlook Today’s Speakers Xueming Qian, Ph.D. Charlie Qi, M.D. Weiwei Liang, MBA Founder, Chairman and CEO EVP, Head of Global R&D, CMO SVP, BD & Corp Strategy, 3 Acting CFO
Slide 4: 1H 2026 Performance Highlights
1H 2026 Performance Highlights Xueming Qian, Ph.D. Founder, Chairman and CEO
Slide 5: 1H2026 Performance Highlights and Subsequent Strategic Developments
1H2026 Performance Highlights and Subsequent Strategic Developments • Ozekibart BLA was filed by partner Inhbibrx and accepted by FDA with PDUFA data of 04/14/2027 Pipeline Progress • Secured a global Phase III clinical collaboration with an MNC for Osemitamab, covering PD-1 supply • Initiated launc
Slide 6: Pipeline Progress
Pipeline Progress Charlie Qi, M.D. EVP, Head of Global R&D, CMO
Slide 7: Pipeline Strategy: Advancing High Potential Pipelines
Pipeline Strategy: Advancing High Potential Pipelines Across Osteoporosis, Oncology and Immunology through Focused Development and Strategic Partnership Bone mAb/BsAb Immunology Oncology BsAb RDC/BsAb/ADC 7
Slide 8: Featuring a Robust Pipeline Across Core Therapeutic Areas
Featuring a Robust Pipeline Across Core Therapeutic Areas Preclinical IND Phase 1 Phase 2 Phase 3 Rights Improved Osteoporosis Therapeutics for Validated Targets Blosozumab (Scl mAb) Osteoporosis U.S. P2 Completed Greater China TST-973 (long-acting) Osteoporosis Global TST-901 (bispecific anti-Scl)
Slide 9: Ozekibart (INBRX-109) BLA Stage
Ozekibart (INBRX-109) A DR5 Agonist for Chondrosarcoma and other Advanced Solid Tumors, for which Transcenta holds rights to develop and commercialize in Greater China BLA Stage 9
Slide 10: Global Registration Enabling Phase 2 Trial Achieved Primary Endpoint of mPFS
Global Registration Enabling Phase 2 Trial Achieved Primary Endpoint of mPFS Designed to Maximize Therapeutic Index of DR5 Activation While Avoiding Normal Tissue Toxicity Ozekibart significantly prolonged mPFS vs placebo and led to 52% reduction in the disease progression or death Transcenta Owns G
Slide 11: Osemitamab (TST001) Clinical Phase 3 Stage
Osemitamab (TST001) A Phase 3-ready, ADCC-enhanced mAb targeting Claudin18.2 with the potential for Best-in-class combination efficacy in 1L Gastric/Gastroesophageal Junction Cancers Clinical Phase 3 Stage 11
Slide 12: Specifically Designed to Produce a Best-in-class Profile Targeting CLDN18.2
Specifically Designed to Produce a Best-in-class Profile Targeting CLDN18.2, Particularly vs. Zolbetuximab (approved 2024, FY25 sales projected $400M USD) A Best-in-class Anti-CLDN18.2 Antibody Synergistic Anti-tumor Activities Seen With PD(L)1 mAb 500 hIgG1+Vehicle 15mg/kg Tumor Volume (mm3) TST001
Slide 13: Phase 2 Study in Combination with PD1 and Chemo in 1L CLDN18.2+ G/GEJC Cancer
Phase 2 Study in Combination with PD1 and Chemo in 1L CLDN18.2+ G/GEJC Cancer Continued to Show Best Therapeutic Potential ORR, DOR, PFS & OS for Patients with PDL1 CPS & CLDN18.2 Known Overall Response Rate Patients Profile CLDN18.2+, all CPS[1] CLDN18.2 + & CPS≥1* HR 0.549 (95% CI 0.302,0.997) CLD
Slide 14: Osemitamab Showed Better Efficacy Against Benchmarks in Cross Trial Comparisons
In Phase 2 Trials, Osemitamab Showed Better Efficacy Against Benchmarks in Cross Trial Comparisons Triple Osemitamab combination in CLDN18.2 (≥40%, ≥2+) & PDL1 CPS-known Group[1] Compared to Nivolumab+Chemo Data in Checkmate 649* and Zolbetuximab+Chemo Data in GLOW** OS (months) mPFS (months) ORR[2]
Slide 15: Global Phase 3 Study Design Overview
Global Phase 3 Study Design Overview All regions (US, Asia, Europe, ROW) 820 patients with CLDN18.2 positive, all PD-L1 CPS Locally Advanced or Includes Japanese cohort with early look at safety Metastatic Locally Advanced or Metastatic Gastric/GEJ Gastric/GEJ Randomization & TST001 + CapOx or mFOLF
Slide 16: Oncology - Portfolio of CLDN18.2 Targeted Therapies
Oncology - Portfolio of CLDN18.2 Targeted Therapies Benefiting Boarder Patient Population with Differentiated Assets Osemitamab (TST001) TST106 TST198 Targeted Radiopharmaceutical Modality Monoclonal antibody Bispecific ADC Therapy Tumor cell killing Enhanced immune-cell mediated Direct tumor cell k
Slide 17: Blosozumab (TST002) Clinical Phase 2b Stage
Blosozumab (TST002) A Phase 2 Sclerostin mAb with Greater Efficacy, Less Frequent Dosing and Potential for USD $500 Million+ Peak Sales in Osteoporosis with High Fracture Risk Clinical Phase 2b Stage 17
Slide 18: Recent FDA Changes and Signals Make Path to Market Faster
Recent FDA Changes and Signals Make Path to Market Faster, More Capital Efficient and with Higher Return on Investment The FDA qualified total hip BMD as a validated surrogate endpoint for osteoporosis drug development. Potential for updated policy requiring one pivotal trial rather than two. 18
Slide 19: Discovery of Sclerostin: A Master Negative Regulator of Osteoblast Stem Cell
Discovery of Sclerostin: A Master Negative Regulator of Osteoblast Stem Cell Sclerosteosis: From Rare Genetic Disorder to Therapeutic Innovation Scientists first discovered a rare genetic disease known as sclerosteosis in an African tribe. It causes excessive growth and hardening of bone tissue, and
Slide 20: Unique Dual Mechanisms and Early Clinical Data Position Blosozumab as Potential Best-In-Class
Unique Dual Mechanisms and Early Clinical Data Position Blosozumab (TST002) as Potential Best-In-Class Therapy in Growing Osteoporosis Market % change from baseline of BMD at lumbar spine Dual Mechanisms of Blosozumab (TST002) after 1 year therapy More potent than all currently available anti-OP med
Slide 21: TST002 Binds on Different Sites on Sclerostin Compared to Romosozumab
TST002 binds on different sites on Sclerostin compared to Romosozumab and does not Impact on Cardiovascular Protective Effect of Loop2 Sclerostin binds with LRP6 via Loop2 Blosozumab Romosozumab Loop1/3 Loop2 Blosozumab Loop1/3 Romosozumab TST002 does not block sclerostin binding with LRP6 Macrophag
Slide 22: Encouraging Phase 1b/2a Efficacy Support Further Clinical Development
Encouraging Phase 1b/2a Efficacy Support Further Clinical Development with Potential for Q2M or Q3M Administration Published Blosozumab SAD Study Results* Blosozumab SAD Study Design D85 lumbar spine BMD % change from baseline in TST002 1200mg，n=6+2 8.00% 6.20% 5.94% 6.00% 4.49% 800mg，n=6+2 3.52% 4.
Slide 23: Global Development Strategy for Osteoporosis
Global Development Strategy for Osteoporosis First patient enrollment in the Phase 2b study of TST002 for high-risk osteoporosis to be completed by year-end. Conduct CMC late phase development for pivotal trial material production Develop SubQ formulation to expand targeting population Initiate deve
Slide 24: Earlier Stage Pipeline
Earlier Stage Pipeline Featuring more than 10 innovative assets for oncology and non-oncology indications 24
Slide 25: TST801: A First-in-class Bifunctional Antibody Fusion Protein
TST801: A First-in-class Bifunctional Antibody Fusion Protein of Anti-BAFF Antibody Fused with TACI • With superior dual neutralization of BAFF and APRIL, TST801 is expected to bring better clinical outcomes • In vivo studies in human BAFF overexpressing transgenic mice demonstrated Best-in-class pr
Slide 26: TST808: A Best-in-class Long-Acting Anti-APRIL for the Treatment of IgAN
TST808: A Best-in-class Long-Acting Anti-APRIL for the Treatment of IgAN with Longer Treatment Interval • APRIL is a validated target for IgAN with first generation mAb showing 50% proteinuria reduction in P3 trial • TST808 is a next generation long-acting biparatopic molecule with higher affinity a
Slide 27: TST013: a BIC LIV-1 ADC Designed to Circumvent Issues of 1st-generation ADC
TST013: a BIC LIV-1 ADC Designed to Circumvent Issues Encountered with the 1st-generation ADC LIV-1 has high prevalence across multiple solid tumors including breast cancer, lung cancer, prostate and melanoma Clinically validated Target in Breast Cancer • The first-generation LIV-1 ADC demonstrated
Slide 28: TST003: GREMLIN-1 is a Novel Target for Multiple Solid Tumor Indications
TST003: GREMLIN-1 is a Novel Target with Potential for Multiple Solid Tumor Indications • Gremlin-1 abrogates BMP signaling in cancer cells and promotes epithelial-mesenchymal transformation and invasion, and negatively correlates with OS • Gremlin-1 is highly upregulated in multiple solid tumor typ
Slide 29: Advancing High Potential Pipelines Across Osteoporosis, Oncology and Immunology
Advancing High Potential Pipelines Across Osteoporosis, Oncology and Immunology through Focused Development and Strategic Partnership S ✦ ◖◗ Oncology Bone Immunology RDC/BsAb/ADC mAb/BsAb mAb/BsAb Focused on GI cancers Growing aging population / Focused on IgAN Huge market Ph3 ready for validated ta
Slide 30: Financial Summary and Strategic Partnerships
Financial Summary and Strategic Partnerships Weiwei Liang, MBA SVP, BD & Corp Strategy, Acting CFO
Slide 31: 2026H1 Financial Results (Non-IFRS)
2026H1 Financial Results (Non-IFRS) Revenue RMB23.6 million Other Income RMB0.2 million 23.6 9.4 2.7 Diversified and 774.1% Differentiated 97.9% 0.2 Diversified and -Differentiated Pipeline 2025H1 2026H1 Pipeline 2025H1 2026H1 R&D Expenses RMB50.5 million SG&A Expenses RMB26.8 million 24.9 26.8 70.8
Slide 32: Events After the Reporting Period
Events After the Reporting Period 1 Executed an asset reversion amendment and received USD4 million cash payment Entered into an agreement for HJB asset disposal for RMB190 million, with completion 2 targeted by Q3 2026, subject to shareholder approval and customary closing conditions 3 Advanced to
Slide 33: Strategic Disposal of HJB CDMO Facility
Strategic Disposal of HJB CDMO Facility Transaction Overview Strategic Rationale ▪ Parties: Transcenta | WuXi Biologics ▪ Transaction: Disposal of selected ▪ Reduce the fixed costs associated with CDMO-related assets operating and maintaining the ▪ Scope: Manufacturing facility and manufacturing fac
Slide 34: Outlook
Outlook Xueming Qian, Ph.D. Founder, Chairman and CEO
Slide 35: Outlook: Strategy to Rapidly Develop High Potential Pipeline Molecules
Outlook Our Strategy is to Rapidly Develop High Potential Pipeline Molecules in Osteoporosis, Oncology and Nephrology via Focused Development and Partnership • Accelerate development of blosozumab (TST002) in osteoporosis • Advance Phase 3 trial for osemitamab (TST001) for solid tumors INVEST • Expa
Slide 36: Q&A Session
Q&A Session Today’s Speakers Xueming Qian, Ph.D. Charlie Qi, M.D. Weiwei Liang, MBA Founder/Chairman/CEO EVP, Head of Global R&D/CMO SVP, BD & Corp Strategy / Acting CFO 36
Slide 37: Thank You
Z TRANSCENTA INNOVATE TO EXCEL THANK YOU! Zr INNOVATE TO EXCEL ZZ, TRANSCENTA Ce